Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dave Gore's Trades That Make Sense -- Ignore unavailable to you. Want to Upgrade?

To: Dave Gore who wrote (2243)	2/4/2002 8:33:53 PM
From: Prophet	Read Replies (2) \| Respond to of 16631

Dave, on the biotech index, I am going to take some time and study it. If I do get the time to do so, I'll publish my findings. I am interested in finding out how this index has reacted over time. With the exception of that brief rally in the Nov-Dec time frame, the sector has not caught a break since last year. Interesting enough, there are companies like MEDI that have done relatively well under the current pressure. The index can easily slide to the 410 level which to me would be a definite bottom. The index lost about 5% today along; ELN alone 15 points off for a nice 50% hair cut. Even CHIR, with strong support at 41.6 has broken down.

To: Dave Gore who wrote (2243)	2/4/2002 8:35:12 PM
From: pompsander	Respond to of 16631

I was fortunate last month to buy back some MSFT/Jan. 70 puts at a nice gain. (MSFT then at 68) I earmarked the freed up capital for some new targets during this step down, but found today that a GTC I had in place for MSFT at 61 was filled. Frankly, did not think this would hit until the possible late summer sell-off some are predicting. Of all the buys I had in place, I would have thought this one least likely to hit first. I like MSFT at this price, but for the darn litigation uncertaities. Still, when creating a billion dollars a month or more in free cash flow, things could be worse.